- García-González, Pablo
- Díaz Belloso, Rafael
- Munoz-Delgado, Laura
- Buiza Rueda, Dolores
- Gómez-Garre, Pilar
- Pérez-Tur, Jordi
- Real, Luis M.
- Bullido, María Jesús
- Ruiz, Agustín
18 páginas, 2 figuras, Progressive supranuclear palsy (PSP) is a rare 4-repeat tauopathy that causes behavioural, movement and cognitive abnormalities. We genotyped all available clinical and histopathological PSP cases in Spain and Portugal (N = 522), and conducted the largest PSP GWAS of the Iberian population to date. Genetic burden analysis revealed reduced diagnostic specificity in clinically diagnosed atypical PSP cases-when applying the 2017 MDS criteria-compared to Richardson's syndrome cases. We independently replicated eight PSP risk variants in seven known loci (MAPT, MOBP, EIF2AK3, STX6, SLCO1A2, DUSP10 and APOE), and identified a novel locus in NFASC/CNTN2 (rs12744678 C: OR[95%CI] = 0.83[0.78-0.89]; p = 4.15·10-08) after meta-analysis with a newly available Dutch cohort and publicly available summary statistics (3,099 PSP; 11,482 controls). Enrichment analysis and protein expression profiling highlighted oligodendrocyte function and myelination as likely contributors to PSP pathogenesis. Our findings broaden the genetic landscape of PSP and suggest potential therapeutic avenues focused on modulating neuron-oligodendrocyte interactions., This work was funded by CIBERNED (Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas) 10th internal call for cooperative projects (Register number: 2019/09). Agustín Ruiz, Pascual Sanchez-Juan, Alberto Rábano, and Maria J. Bullido received funding from this convocatory. Pablo García-González received support by CIBERNED employment plan CNV-304-PRF-866. CIBERNED is integrated into ISCIII (Instituto de Salud Carlos III). Mercé Boada, Marta Marquié and Agustín Ruiz are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PI19/00335 and PI22/011403, and CIBERNED grant 2019/08. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). Agustín Ruiz is supported by ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). He is also supported by the STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Health. USA. (P30AG066546), the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer’s and Neurodegenerative Diseases (2024-2025) and Patricia Ruth Frederick Distinguished Chair for Precision Therapeutics in Alzheimer’s and Neurodegenerative Diseases (2025-2028). The genotyping service to generate GR@ACE and PSP/DEGESCO GWAS data was carried out at CEGEN-PRB3-ISCIII; it is supported by grant PT17/0019, of the PE I + D + i 2013-2016, funded by ISCIII and ERDF”. Itziar de Rojas received support by a national grant from ISCIII FI20/00215. Amanda Cano acknowledges the support of the Spanish Ministry of Science, Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I), the support of ISCIII under the grant Sara Borrell (CD22/00125), Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00, and Fundación ADEY under the program “Proyectos de Investigación en Salud 2023”. Fondo de Investigacion en Salud (Instituto Carlos III) (PI17/00096) in the frame of the European Regional Development Fund (ERDF) and to Fundacio ́ la Marato ́ de TV3 (PI043296 and 202009-10). This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019). Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017) from Andalusian Regional Ministry of Health. Laura Muñoz-Delgado was supported by the “Río Hortega” program [CM21/00051] from the Instituto de Salud Carlos III (ISCIII-FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Sven J. van der Lee was funded for this study by NWO (#733050512, PROMO-GENODE: a PROspective study of MOnoGEnic causes Of Dementia) a substantial donation by Edwin Bouw Fonds and Dioraphte. SvdL further received funding for the GeneMINDS consortium, which is powered by Health~Holland, Top Sector Life Sciences & Health. Sven J. van der Lee is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. ABOARD also receives funding from de Hersenstichting, Edwin Bouw Fonds and Gieskes-Strijbisfonds. Array genotyping was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). This work has been supported by the Queen Sofia Foundation. Pascual Sánchez-Juan is supported by grants from ISCIII (PMP22/00022 and PI20/01011) and TED2021-131676B-100. Luis Miguel Real received support from “The absence of seroconversion after exposition to hepatitis C virus is not related to KIR-HLA genotype combinations” (GEHEP-012 study). Consejería de Salud de la Junta de Andalucía (grant number PI-0001/2017) and CIBERINFEC -Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas- Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación y Unión Europea (Spain) (NextGeneration EU) (grant number CB21/13/00118). Jose Luis Royo received support from Project 23.04.2021 from Santángela Foundation (Sevilla, Spain)., Peer reviewed
Project:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) / PI13-02434
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) / PI16-01861
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) / PI17-01474
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 / PI19-01301
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) / PI19-00335
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) / PID2021-122473OA-I00
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) / PI17-00096
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) / PI14-01823
,
MINECO / PI16-01575
,
ISCIII / PI18-01898
,
ISCIII / PI19-01576
,
ISCIII / PI21-01875
,
ISCIII / PMP22